Sonnet biotherapeutics provides fiscal year 2023 business overview

Following the recent completion of a $4.55 million financing, sonnet projects cash runway into the calendar year third quarter of 2024 the company is focused on its business development initiatives and anticipates being able to provide an update in the next few quarters the company continues to advance its therapeutic pipeline with the initiation of the sb221 study with son-1010 in platinum-resistant ovarian cancer (proc); early safety data from the son-080 study in cipn are expected before the end of 2023 princeton, nj / accesswire / october 31, 2023 / sonnet biotherapeutics holdings, inc., (nasdaq:sonn) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, provided a fiscal year 2023 business overview. "as has been our objective since the company's founding, we are committed to innovating next generation cancer treatments of significant potential utility for patients and caregivers, alike," commented pankaj mohan, ph.d.
SONN Ratings Summary
SONN Quant Ranking